ClinicalTrials.gg
TerminatedNCT05760612Updated Nov 20, 2026

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

A Phase 3 interventional study of Trastuzumab and neratinib and Trastuzumab and Pertuzumab in Early-stage Breast Cancer, HER2-positive Breast Cancer and Adjuvant Treatment After Trastuzumab, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Terminated at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Phase 3, Interventional, and Treatment

How we know · 8 judgments

Why this study was terminated
Poor accrual
Updated Nov 20, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
137th of 366
90 · median 61
Started
2023
with 10 others
Phase 3
60 of 374
3 open now
Registered
329th of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 137th largest by enrollment of the 366 interventional ones that give a count, is one of 11 that started in 2023, is one of 60 in phase 3, and was the 329th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

Neratinib is an irreversible pan-HER tyrosine kinase inhibitor (TKI). Currently, no studies have investigated the use of macromolecular anti-HER2 agents combined with TKIs for the treatment of non-pCR HER2-positive breast cancer following neoadjuvant therapy. Furthermore, there are no prospective randomized controlled trials comparing trastuzumab plus pertuzumab versus trastuzumab plus TKIs in HER2-positive breast cancer patients with residual cancer burden class (RCB) I or II after neoadjuvant trastuzumab and pertuzumab. Therefore, this study aimed to evaluate the efficacy and safety of adjuvant trastuzumab plus neratinib in patients with hormone receptor-positive/HER2-positive breast cancer and RCB 0/I following neoadjuvant trastuzumab and pertuzumab therapy.

03

Conditions studied

  • Early-stage Breast Cancer
  • HER2-positive Breast Cancer
  • Adjuvant Treatment After Trastuzumab
  • RCB Classification 1-2
  • Neratini

Browse trials for

Keywords

  • Hormone receptor positive HER2 positive breast cancer
  • targeted therapy
  • adjuvant therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients aged 18-70 years;
  2. performance status of 0 or 1;
  3. Clinical stage at initial diagnosis (per the 8th edition of the American Joint Committee on Cancer Staging Manual): cT1-4/N1-3/M0 (cT1mi/N0 or cT1a-b/N0 are eligible), meeting the criteria for therapy as per NCCN 2022 guidelines;
  4. confirmed hormone receptor-positive (estrogen receptor ≥1% and/or progesterone receptor ≥1%) and -positive (immunohistochemistry 3+ or fluorescence in situ hybridization-positive) invasive breast cancer;
  5. Completion of ≥4 cycles of neoadjuvant therapy with trastuzumab and pertuzumab, without recurrence or disease prior to adjuvant treatment; residual cancer burden class 0 or I after neoadjuvant therapy; time from initial surgery to randomization ≤12 weeks;
  6. Adequate organ function within 2 weeks prior to screening (without transfusion or use of growth factors):

    • ≥1.5 × 10⁹/L;
    • count ≥90 × 10⁹/L;
    • ≥90 g/L;
    • Total ≤1.5 × (ULN);
    • and aspartate aminotransferase ≤1.5 × ULN;
  7. Post-neoadjuvant therapy echocardiography showing (LVEF) ≥50% during screening, with an absolute decrease of ≤15% compared to pre-chemotherapy values; if no pre-chemotherapy LVEF assessment is available, LVEF must be ≥55% during screening;
  8. ≥6 months;
  9. For premenopausal or non-sterilized female patients: agreement to abstain from sexual activity or use effective non-hormonal during study treatment and for 8 weeks after the last dose;
  10. Willingness to participate voluntarily, provide signed , demonstrate good compliance, and cooperate with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. History of local or regional breast cancer recurrence;
  2. Clinical stage IV () breast cancer;
  3. Bilateral breast cancer;
  4. History of other malignant tumors within the past 5 years, except for curatively treated cervical carcinoma in situ, basal cell carcinoma, or cutaneous squamous cell carcinoma;
  5. Prior treatment with pyrotinib, lapatinib, neratinib, or other tyrosine kinase inhibitors; trastuzumab emtansine; or any antitumor biological or immunotherapy;
  6. Concurrent participation in another clinical trial involving antitumor therapy, including endocrine therapy, bisphosphonate therapy, or immunotherapy;
  7. Significant cardiac disease, including:

    • Heart failure or systolic dysfunction ( \< 50%);
    • Poorly controlled arrhythmias (e.g., atrial tachycardia, significant ventricular arrhythmia, or high-grade atrioventricular block);
    • Angina requiring antianginal medication;
    • valvular heart disease;
    • Electrocardiographic evidence of transmural myocardial infarction;
    • Poorly controlled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg) despite medication;
  8. Impaired drug absorption due to dysphagia, intestinal obstruction, or other gastrointestinal disorders;
  9. History of neurological or psychiatric conditions that may compromise compliance or ;
  10. Chronic gastrointestinal disorders with predominant diarrhea;
  11. Known to any study drug components; history of immunodeficiency (e.g., positivity, congenital or acquired immunodeficiency disorder), or prior organ transplantation;
  12. Pregnancy, lactation, or positive pregnancy test at baseline in women of ;
  13. Severe comorbidities that may interfere with treatment, including active infections (e.g., , , tuberculosis, syphilis) or any other condition deemed by the investigator to render the patient unsuitable for trial participation.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    Trastuzumab combined with Pertuzumab

    Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and pertuzumab (840 mg IV loading dose, followed by 420 mg IV once every 3 weeks). This regimen will be repeated for a total of 18 cycles,encompassing both the preoperative and adjuvant phases.

    Drug: Trastuzumab and Pertuzumab

  • Experimental
    Trastuzumab combined with neratinib

    Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and neratinib 240 mg orally once daily. The trastuzumab treatment will be continued for a total of 18 cycles, encompassing both the preoperative and adjuvant phases, while neratinib will be maintained throughout the adjuvant period.

    Drug: Trastuzumab and neratinib

Interventions

  • DrugTrastuzumab and neratinib

    Drug pages: TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · NeratinibStudies of NeratinibNeratinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and neratinib 240 mg orally once daily. The trastuzumab treatment will be continued for a total of 18 cycles, encompassing both the preoperative and adjuvant phases, while neratinib will be maintained throughout the adjuvant period.

  • DrugTrastuzumab and Pertuzumab

    Drug pages: TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PertuzumabStudies of PertuzumabPertuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and pertuzumab (840 mg IV loading dose, followed by 420 mg IV once every 3 weeks). This regimen will be repeated for a total of 18 cycles,encompassing both the preoperative and adjuvant phases.

06

What researchers measure

Primary outcomes

  1. Invasive disease free survival, IDFS

    The time from random assignment until the first occurrence of invasive disease recurrence, distant recurrence, or death from any cause.

    Time frame: During the 3 years after random assignment

Secondary outcomes

  1. Disease free survival, DFS

    The time from random assignment until recurrence, the development of a second cancer, or death from any cause.

    Time frame: During the 3 years after random assignment

  2. Overall survival, OS

    The time from randomization to death from any cause.

    Time frame: During the 3 years after random assignment

  3. Distant disease free survival, DDFS

    The time from random assignment until the first occurrence of distant recurrence or death from any cause.

    Time frame: During the 3 years after random assignment

  4. Incidence and severity of adverse events

    The incidence and severity of adverse events will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).

    Time frame: From signing the informed consent form until 28 days after completion of adjuvant treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2023 to primary completion in Sep 2026, 42 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Feb 2028 → Sep 2026 and completion Nov 2028 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2023
First posted
Mar 8, 2023
StartActual
Mar 14, 2023
Primary completionActual
Sep 23, 2026was Feb 2028
CompletionActual
Oct 23, 2026was Nov 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Poor accrual
changed Nov 20, 2026
Primary completion
Feb 16, 2028→Sep 23, 2026 (actual)
Nov 20, 2026
Study completion
Nov 1, 2028→Oct 23, 2026 (actual)
Nov 20, 2026
Enrollment
300 (estimated)→90 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Terminated
    Why stopped Poor accrual
    Primary completion Feb 16, 2028→Sep 23, 2026 (now actual)
    Study completion Nov 1, 2028→Oct 23, 2026 (now actual)
    Enrollment 300 (estimated)→90 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05760612
Responsible party
Chang Gong (Chief physician, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Mar 8, 2023
Start date
Mar 14, 2023
Primary completion
Sep 23, 2026
Completion
Oct 23, 2026
Last update
Nov 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab · Neratinib

Start the discussion